Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageJazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease – often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering R&D advancements across our robust pipeline of innovative therapeutics.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Business segments
Q2 2026 · $1.15BThe company’s own SEC segment disclosure.
- Oncology$362.3M31%
- Epilepsy$292.1M25%
- Zepzelca$105.8M9%
- Rylaze Enrylaze$99.5M9%
- Defitelio Defibrotide$62.0M5%
- Product And Services Royalties And Contract$52.2M5%
- Other (6)$177.7M15%
Jazz Pharmaceuticals plc (JAZZ) reported revenue of $1.07B in Q1 2026 (quarter ended March 31, 2026), up 19% from the same quarter a year earlier. That came with net income of $293M (27% of revenue). For the full year FY2025, revenue was $4.27B (+4.9% year on year) and net income −$356M. Its largest product in 2026-Q2 was Oncology at $362M, 31% of the disclosed total, just ahead of Epilepsy at 25%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.